Sanofi is now the third insulin maker to cut prices

S:Anofi will cut the US list price of two of its insulins, making it the third major diabetes drug maker to cut prices recently.

French drugmaker Sanofi will cut the US list price of Lantus, its most-prescribed insulin, by 78%, it said in a statement Thursday. The company will also reduce the list price of Apidra by 70%.

“We are pleased to see others join our efforts to help patients as we now accelerate the transformation of the US insulin market,” said Olivier Beauguillot, US Generics Head. “Our decision to lower the list price of our lead insulin must be combined with a broader system-wide change to actually deliver savings for patients at the pharmacy counter.”

Read more: Insulin isn’t the only high cost for people with diabetes

The company will also cap the cost of Lantus at $35. The moves, which take effect in 2024, mirror moves by rivals Eli Lilly & Co and Novo Nordisk A/S.

The price cuts from the big three insulin players follow pressure from lawmakers and advocates who have raised concerns about affordability for patients. Companies could also reap financial benefits from lower prices next year due to an upcoming change in how much manufacturers can pay in Medicaid rebates.

Novo announced Tuesday that it will cut the list prices of NovoLog and NovoLog Mix 70/30 by 75%. The company is also cutting prices for Novolin and Levemir, as well as several off-brand insulins. Lilly, which first announced the price changes earlier this month, will drop the prices of Humalog and Humulin by 70% and cap out-of-pocket costs at $35.

More must-reads from TIME

Contact us at

Source link